Study wrapper · #1336
Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities.
Editor's note
A useful, unglamorous review of the central problem in oral peptide delivery. The counterintuitive point is that despite large swings in individual absorption, steady-state exposure stays relatively stable because semaglutide's roughly week-long half-life and extensive albumin binding smooth day-to-day differences. Nothing here changes clinical practice, but it clarifies why the fasting-and-limited-water dosing instructions are load-bearing rather than advisory. The formulation candidates discussed remain preclinical or early-stage.
Plain-language abstract
Oral semaglutide is absorbed poorly: roughly 0.4 to 1 percent of the dose reaches the bloodstream under fasted conditions, and blood levels are essentially undetectable if it is taken with food. This review explains why the gut degrades and blocks the peptide, how the absorption enhancer SNAC partly compensates by raising local stomach pH, and which nanoformulations, enzyme inhibitors and delivery devices are being explored next.